Lavelle Erin
SEC-identified person · CIK 1737613 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Jade Biosciences, Inc. JBIO | Director | filed 2025–2026 |
| Avalyn Pharma Inc. AVLN | Director | filed 2026–2026 |
| Neurogene Inc. NLTX | Director | filed 2022–2023 |
| Eliem Therapeutics, Inc. ELYM | COO & CFO | filed 2021–2022 |
| Alder Biopharmaceuticals INC ALDR | Chief Operating Officer | filed 2018–2019 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.